Windlas Biotech Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/es4kmpgi0oortbnj8g1jin4g.pdf

Key Takeaways


CDMO: The Core Growth Engine

Hitesh Windlass: "So schedule M compliance is not just about capital -- access to capital. It is about know-how, it is about talent and it is about systems. How do we maintain whatever we -- even if you achieve it once, then how do you stay compliant?"

Trade Generics: Growth Interrupted


Exports: Small Base, Binary Outcomes

Hitesh Windlass: "Avnish, so the -- as you correctly mentioned and I want to just reinforce, we have 0 sales to U.S. and 0 sales to Europe, right?"

Plant 6: The Next Capacity Catalyst

Hitesh Windlass: "The capacity utilization number is a very competitive number, right? Because when you disclose that, your competitors understand how desperate -- and your customers also understand how desperate you are for business."

Margins & Financial Discipline


Strategy & Competitive Positioning

Komal Gupta: "We would rather try to surprise you pleasantly. That is the intent and that is the effort is what I can tell you how we are able to execute it depends."

Guidance & Commitments

CommitmentSpecificsTimeline
Plant 6 mechanical completionMechanical completion achievedEnd of FY26
Plant 6 commercializationReady for commercialization, partial contribution possible earlierH1 FY27
Plant 6 depreciation startCapitalization in H1, depreciation begins under WDV methodQ2 or Q3 FY27
Plant 6 market focusNot targeting US or Europe; focused on India verticalsOngoing
Export market focusZero sales to US, zero sales to Europe; focus on RoW and semi-regulated marketsOngoing

Key Metrics

MetricQ3 FY26
Revenue from operations₹233 crores, +20% YoY
9M FY26 revenue from operations₹666 crores, +19% YoY
EBITDA (reported)₹24 crores
EBITDA margin (reported)10.3% (per an analyst's math)
EBITDA (excl. ESOP)₹32 crores, 13.6% of revenue
PAT (reported)₹15 crores
PAT margin (reported)6.4% (per an analyst's math)
PAT (excl. ESOP)₹22 crores, 9.6% of revenue
9M FY26 EPS₹24.02, +12% YoY
Generic Formulations CDMO vertical growth+23% YoY
Trade Generics and Institutional verticals growth+7% YoY
Exports vertical growth+36% YoY
Indian pharma market growth11.8% YoY, volume growth of 1.6%
Plant 6 expected remaining capex~₹10 crores, total expected capex ₹50-60 crores
Quarterly depreciation run rate₹7.6-7.7 crores
Consecutive quarters of highest ever revenue12 quarters